Protease inhibitor (PI) combination is the one of second-line therapy in HIV infections after resistant with another Highly Active Antiretroviral Therapy (HAART), and significantly to give a good prognostic output. Some studies showed the metabolic effect after using PI, such as dyslipidemia and lipodystrophy syndrome. The association between using PI that cause hypertension and decrease of renal function poorly definited.
This study was aimed to explain the effect between PI as a second-line therapy with hypertension and renal function among HIV patients.
A longitudinal study who involved 311 HIV patients in VCT Clinic, Sanglah General Hospital between April to June 2016. After data cleaning, 79 patients were excluded because did not fulfil inclusion and exclusion criteria. The collected data include: gender, age, body weight, CD4 level, stadium (WHO), ARV regimen, duration of ART, blood pressure, and renal function test. Data were analyzed using SPSS with univariate and bivariate analysis (chi-square test).
From a total 232 samples, 72% were males, and the majority of samples age in range 30-40 years old (49.1%). We found 15.1% patients had used PI. The prevalence of hypertension among HIV patients in VCT Clinic Sanglah General Hospital is 20.8%. There was significant association between group who undergoing therapy with PI and hypertension (p < 0.0001). we also found positive correlation between using protease inhibitor with decrease of renal function (p < 0.05).
Protease inhibitor as a second-line ARV showed the effect can cause hypertension and decrease of renal function among HIV patients. Other factors may cause hypertension and decrease of renal function that include BMI, smoking, alcohol, another medication, and metabolic disease.
1Faculty of Medicine, Udayana University
2Division of Tropic and Infectious Diseases, Department of Internal Medicine, Faculty of Medicine, Udayana University/Sanglah General Hospital